Abstract
Significance: The 2025 Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking discoveries concerning peripheral immune tolerance, specifically identifying the FOXP3 gene as the master regulator of regulatory T cells (Tregs). Their work demonstrated that FOXP3 mutations cause severe autoimmune disease (IPEX syndrome), establishing FOXP3 as essential for immune self-tolerance. This study demonstrates that Metadichol significantly upregulates FOXP3 expression (5.46-fold), providing a novel pharmacological approach to enhance regulatory T-cell function and immune homeostasis—directly relevant to the Nobel Prize-winning discoveries.
Background: Forkhead box (FOX) transcription factors constitute a large family of regulatory proteins that control diverse cellular processes, including development, metabolism, immunity, and aging. Metadichol, a nano lipid formulation derived from long-chain alcohols, has demonstrated pleiotropic biological effects, including immunomodulation and metabolic regulation.
Objective: To comprehensively evaluate the effects of metadichol treatment on FOX transcription factor gene expression in human peripheral blood mononuclear cells (PBMCs) via quantitative PCR analysis.
Methods: Human PBMCs were isolated via Histopaque density gradient centrifugation and treated with Metadichol at concentrations of 1 pg/ml, 100 pg/ml, 1 ng/ml, and 100 ng/ml. Total RNA was extracted, reverse-transcribed, and analyzed by quantitative PCR for 45 FOX genes. Gene expression changes were calculated via normalization to GAPDH via the 2^-ΔΔCq method.
Results: Metadichol treatment resulted in dose-dependent modulation of FOX gene expression. At the highest concentration (100 ng/ml), significant upregulation of multiple FOX genes was observed, with FOXO1 showing the greatest increase (8.74-fold), followed by FOXA1 (7.39-fold) and FOXH1 (7.22-fold). Additional substantial increases were noted for FOXA2 (6.57-fold), FOXA3 (6.98-fold), FOXB1 (6.79-fold), FOXP3 (5.46-fold), and FOXP4 (6.23-fold). Conversely, selective downregulation was observed for FOXL2 (0.16-fold), FOXL1 (0.54-fold), and FOXD4L1 (0.56-fold).
Conclusions: Metadichol has potent and selective effects on FOX transcription factor expression in human PBMCs, with preferential upregulation of genes involved in metabolic regulation, immune homeostasis, induced pluripotency and cellular longevity pathways. These findings suggest potential therapeutic applications in age-related diseases, metabolic disorders, and immunomodulation, and regenerative medicine. Importantly, the coordinated upregulation of pluripotency-associated genes, including FOXD3, FOXO1, and FOXM1, establishes Metadichol as a compelling modulator of cellular reprogramming networks with significant implications for advancing stem cell-based regenerative therapies. The differential expression patterns indicate complex regulatory mechanisms that warrant further investigation to elucidate their clinical translation potential.